Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

1.19
+0.01501.28%
Volume:31.89K
Turnover:37.23K
Market Cap:23.18M
PE:-2.01
High:1.19
Open:1.17
Low:1.14
Close:1.17
Loading ...

BRIEF-Lexaria Bioscience Says Unit Finalizes Project Agreement With Novotech

Reuters
·
19 Dec 2024

Lexaria Bioscience Corp - Unit Finalizes Project Agreement With Novotech

THOMSON REUTERS
·
19 Dec 2024

Lexaria Bioscience Bolsters Drug Delivery Strategy

TIPRANKS
·
19 Dec 2024

Lexaria Bioscience forms Scientific Advisory Board

TIPRANKS
·
18 Dec 2024

Lexaria Forms New Scientific Advisory Board

ACCESSWIRE
·
18 Dec 2024

Lexaria Bioscience Welcomes New Chief Medical Advisor

TIPRANKS
·
18 Dec 2024

Lexaria Bioscience appoints Michael Gibson as chief medical advisor

TIPRANKS
·
17 Dec 2024

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

ACCESSWIRE
·
17 Dec 2024

Lexaria Bioscience Explores Oral Liraglutide Potential

TIPRANKS
·
10 Dec 2024

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

TIPRANKS
·
09 Dec 2024

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

ACCESSWIRE
·
09 Dec 2024

LEXX: Phase I Start Imminent

Zacks Small Cap Research
·
05 Dec 2024

Lexaria Bioscience Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
02 Dec 2024

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals

Newsfile
·
01 Dec 2024

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
28 Nov 2024

BRIEF-Lexaria Bioscience Files Prospectus For Resale From Time To Time By Selling Stockholder Of Up To 4.6 Million Shares Of Common Stock - SEC Filing

Reuters
·
27 Nov 2024

Lexaria Bioscience Files Prospectus for Resale From Time to Time by Selling Stockholder of up to 4.6 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
27 Nov 2024

Lexaria Bioscience’s Promising Outlook on GLP-1 Drugs

TIPRANKS
·
27 Nov 2024

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

ACCESSWIRE
·
26 Nov 2024

Lexaria Bioscience Corp: Lexaria's Glp-1 Human Pilot Study #3 Completes Dosing as Scheduled

THOMSON REUTERS
·
25 Nov 2024